.png)
About the United Kingdom Atomic Energy Authority
UKAEA is the national organisation responsible for the research and delivery of sustainable fusion energy. It is an executive non-departmental public body, sponsored by the Department for Energy Security and Net Zero.
UKAEA runs the fusion machine MAST-Upgrade (Mega Amp Spherical Tokamak)and is delivering the transition of JET from plasma operations to repurposing and decommissioning. The insights gained from this process will contribute tothe advancement of sustainable future fusion power plants.
STEP (Spherical Tokamak for Energy Production) is a major technology and infrastructure programme that will demonstrate net energy from fusion, fuel self-sufficiency and a route to plant maintenance. UKAEA is STEP’s fusion partner and will work alongside STEP’s industry partners – one in engineering and one in construction – with the following short-list announced here.
The STEP programme is being delivered by UK Industrial Fusion Solutions Ltd (UKIFS) a wholly owned subsidiary of UKAEA Group. UKIFS will lead STEP’s integrated delivery team to design and build the prototype plant at West Burton site in Nottinghamshire, targeting first operations in 2040.
UKAEA is now engaging in Fusion Futures, a programme that aims to foster world-leading innovation whilst stimulating general industry capacity through international collaboration and the development of future fusion power plants.
UKAEA also undertakes cutting-edge work with research organisations and the industrial supply chain in a wide spectrum of areas, including robotics and materials.
More information: https://www.gov.uk/ukaea.
Social Media: @UKAEAofficial
About SHINE Technologies
Headquartered in Janesville, Wisconsin, SHINE Technologies stands as an industry leader in next-generation fusion, deploying innovative fusion and fusion-based technology that seamlessly combines safety, cost-efficiency, and environmental responsibility.
Distinguished by its proprietary medical isotope production processes, SHINE is at the forefront of creating non-carrier-added lutetium-177—a vital component in cutting-edge medical treatments. Anticipating further advancements, the company's forward-looking vision includes the creation of molybdenum-99, a diagnostic tool that plays a pivotal role in medical procedures aimed at detecting heart disease and cancer.
SHINE's commitment to innovation extends beyond the realms of industry and healthcare. Drawing on its fusion-technology expertise, the company has set its sights on addressing one of energy's most complex challenges—nuclear waste recycling. With a comprehensive and visionary approach, SHINE is steadfastly driving advancements across multiple sectors, leaving an indelible mark on the domains of technology, healthcare, and sustainable energy solutions.
Press Contact: press@shinefusion.com
